FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107181087> ?p ?o ?g. }

• W2107181087 endingPage "1551" @default.
• W2107181087 startingPage "1543" @default.
• W2107181087 abstract "Background Malaria remains a leading global health problem that requires the improved use of existing interventions and the accelerated development of new control methods. We aimed to assess the safety, immunogenicity, and initial efficacy of the malaria vaccine RTS,S/AS02D in infants in Africa. Methods We did a phase I/IIb double-blind randomised trial of 214 infants in Mozambique. Infants were randomly assigned to receive three doses either of RTS,S/AS02D or the hepatitis B vaccine Engerix-B at ages 10 weeks, 14 weeks, and 18 weeks of age, as well as routine immunisation vaccines given at 8, 12, and 16 weeks of age. The primary endpoint was safety of the RTS,S/AS02D during the first 6 months of the study, and analysis was by intention to treat. Secondary endpoints included immunogenicity and analysis of new Plasmodium falciparum infections during a 3-month follow up after the third dose. Time to new infections in the per-protocol cohort were compared between groups using Cox regression models. This study is registered with ClinicalTrials.gov, number NCT00197028. Findings There were 17 children (15.9%; 95% CI 9.5–24.2) with serious adverse events in each group. In the follow-up which ended on March 6, 2007, there were 31 serious adverse events in the RTS,S/AS02D group and 30 serious adverse events in the Engerix-B group, none of which were reported as related to vaccination. There were four deaths during this same follow-up period; all of them after the active detection of infection period had finished at study month 6 (two in RTSS/AS02D group and two in the Engerix-B group). RTS,S/AS02D induced high titres of anti-circumsporozoite antibodies. 68 first or only P falciparum infections were documented: 22 in the RTS,S/AS02D group and 46 in the control group. The adjusted vaccine efficacy was 65.9% (95% CI 42.6–79.8%, p<0.0001). Interpretation The RTS,S/AS02D malaria vaccine was safe, well tolerated, and immunogenic in young infants. These findings set the stage for expanded phase III efficacy studies to confirm vaccine efficacy against clinical malaria disease." @default.
• W2107181087 created "2016-06-24" @default.
• W2107181087 creator A5013809378 @default.
• W2107181087 creator A5014548384 @default.
• W2107181087 creator A5015438763 @default.
• W2107181087 creator A5016959845 @default.
• W2107181087 creator A5018831973 @default.
• W2107181087 creator A5019029049 @default.
• W2107181087 creator A5019096476 @default.
• W2107181087 creator A5020521015 @default.
• W2107181087 creator A5028720398 @default.
• W2107181087 creator A5030515780 @default.
• W2107181087 creator A5039781450 @default.
• W2107181087 creator A5043650852 @default.
• W2107181087 creator A5051476386 @default.
• W2107181087 creator A5058335415 @default.
• W2107181087 creator A5069459097 @default.
• W2107181087 creator A5077528263 @default.
• W2107181087 creator A5080086000 @default.
• W2107181087 creator A5081603649 @default.
• W2107181087 creator A5082376915 @default.
• W2107181087 creator A5082420204 @default.
• W2107181087 creator A5091710844 @default.
• W2107181087 creator A5091817249 @default.
• W2107181087 date "2007-11-01" @default.
• W2107181087 modified "2023-10-18" @default.
• W2107181087 title "Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial" @default.
• W2107181087 cites W1989409342 @default.
• W2107181087 cites W2038910210 @default.
• W2107181087 cites W2072984816 @default.
• W2107181087 cites W2074122062 @default.
• W2107181087 cites W2108075232 @default.
• W2107181087 cites W2112558871 @default.
• W2107181087 cites W2124971883 @default.
• W2107181087 cites W2139533311 @default.
• W2107181087 cites W2155144810 @default.
• W2107181087 cites W2267991565 @default.
• W2107181087 cites W2340524139 @default.
• W2107181087 cites W4323874647 @default.
• W2107181087 doi "https://doi.org/10.1016/s0140-6736(07)61542-6" @default.
• W2107181087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17949807" @default.
• W2107181087 hasPublicationYear "2007" @default.
• W2107181087 type Work @default.
• W2107181087 sameAs 2107181087 @default.
• W2107181087 citedByCount "260" @default.
• W2107181087 countsByYear W21071810872012 @default.
• W2107181087 countsByYear W21071810872013 @default.
• W2107181087 countsByYear W21071810872014 @default.
• W2107181087 countsByYear W21071810872015 @default.
• W2107181087 countsByYear W21071810872016 @default.
• W2107181087 countsByYear W21071810872017 @default.
• W2107181087 countsByYear W21071810872018 @default.
• W2107181087 countsByYear W21071810872019 @default.
• W2107181087 countsByYear W21071810872020 @default.
• W2107181087 countsByYear W21071810872021 @default.
• W2107181087 countsByYear W21071810872022 @default.
• W2107181087 countsByYear W21071810872023 @default.
• W2107181087 crossrefType "journal-article" @default.
• W2107181087 hasAuthorship W2107181087A5013809378 @default.
• W2107181087 hasAuthorship W2107181087A5014548384 @default.
• W2107181087 hasAuthorship W2107181087A5015438763 @default.
• W2107181087 hasAuthorship W2107181087A5016959845 @default.
• W2107181087 hasAuthorship W2107181087A5018831973 @default.
• W2107181087 hasAuthorship W2107181087A5019029049 @default.
• W2107181087 hasAuthorship W2107181087A5019096476 @default.
• W2107181087 hasAuthorship W2107181087A5020521015 @default.
• W2107181087 hasAuthorship W2107181087A5028720398 @default.
• W2107181087 hasAuthorship W2107181087A5030515780 @default.
• W2107181087 hasAuthorship W2107181087A5039781450 @default.
• W2107181087 hasAuthorship W2107181087A5043650852 @default.
• W2107181087 hasAuthorship W2107181087A5051476386 @default.
• W2107181087 hasAuthorship W2107181087A5058335415 @default.
• W2107181087 hasAuthorship W2107181087A5069459097 @default.
• W2107181087 hasAuthorship W2107181087A5077528263 @default.
• W2107181087 hasAuthorship W2107181087A5080086000 @default.
• W2107181087 hasAuthorship W2107181087A5081603649 @default.
• W2107181087 hasAuthorship W2107181087A5082376915 @default.
• W2107181087 hasAuthorship W2107181087A5082420204 @default.
• W2107181087 hasAuthorship W2107181087A5091710844 @default.
• W2107181087 hasAuthorship W2107181087A5091817249 @default.
• W2107181087 hasConcept C126322002 @default.
• W2107181087 hasConcept C159654299 @default.
• W2107181087 hasConcept C168563851 @default.
• W2107181087 hasConcept C187212893 @default.
• W2107181087 hasConcept C197934379 @default.
• W2107181087 hasConcept C202953159 @default.
• W2107181087 hasConcept C203014093 @default.
• W2107181087 hasConcept C203092338 @default.
• W2107181087 hasConcept C22070199 @default.
• W2107181087 hasConcept C2777382497 @default.
• W2107181087 hasConcept C2778048844 @default.
• W2107181087 hasConcept C2778371730 @default.
• W2107181087 hasConcept C2780868878 @default.
• W2107181087 hasConcept C2781034427 @default.
• W2107181087 hasConcept C71924100 @default.
• W2107181087 hasConceptScore W2107181087C126322002 @default.
• W2107181087 hasConceptScore W2107181087C159654299 @default.
• W2107181087 hasConceptScore W2107181087C168563851 @default.

• next